| 2019 | 2018 | 2017 | 2016 | 2015 |
Ocular Therapeutix™ Provides Legal Update
December 22, 2017
Ocular Therapeutix™ to Participate in the Guggenheim Securities 5th Annual Boston Healthcare Conference
December 05, 2017
Ocular Therapeutix™ Reports Third Quarter 2017 Financial Results and Provides Corporate Update
November 07, 2017
Ocular Therapeutix™ to Report Third Quarter 2017 Financial Results
October 31, 2017
Ocular Therapeutix™ Appoints Donald Notman as Chief Financial Officer
September 25, 2017
Ocular Therapeutix™ Appoints Michael Goldstein, M.D., M.B.A., as Chief Medical Officer
September 08, 2017
Ocular Therapeutix™ to Present at Three Upcoming Investor Conferences
September 06, 2017
Ocular Therapeutix™ Reports Second Quarter 2017 Financial Results and Provides Corporate Update
August 08, 2017
Ocular Therapeutix™ Appoints Daniel Bollag, Ph.D., as Senior Vice President, Regulatory Affairs, Pharmacovigilance and Quality
August 03, 2017
Ocular Therapeutix™ Announces Antony Mattessich Assumes Role as Chief Executive Officer
August 01, 2017
Ocular Therapeutix™ to Report Second Quarter 2017 Financial Results
July 31, 2017
Ocular Therapeutix™ Receives Complete Response Letter from FDA for DEXTENZA™ NDA
July 11, 2017
Ocular Therapeutix™ Submits Amendment to Potentially Extend Review for DEXTENZA™ New Drug Application (NDA)
July 10, 2017
Ocular Therapeutix™ Reports Inducement Grant Under NASDAQ Listing Rule 5635(c)(4)
June 26, 2017
Ocular Therapeutix™ Announces Executive Transition Plans
June 22, 2017
Ocular Therapeutix™ to Present at Two Upcoming Investor Conferences
June 01, 2017
Ocular Therapeutix™ Presented Phase 3 Data for DEXTENZA™ at the Association for Research in Vision and Ophthalmology (ARVO) Annual Meeting
May 11, 2017
Ocular Therapeutix™ Presents Preclinical Data on Pharmacokinetics, Efficacy and Tolerability of Sustained Release Intravitreal Tyrosine Kinase Inhibitor Hydrogel Depot (OTX-TKI) at the ARVO Annual Meeting
May 09, 2017
Ocular Therapeutix™ Presents Additional Phase 3 Data and Patient Reported Outcomes Results for DEXTENZA™ at the American Society of Cataract and Refractive Surgery (ASCRS) Symposium
May 08, 2017
Ocular Therapeutix™ Reports First Quarter 2017 Financial Results
May 05, 2017
Ocular Therapeutix™ to Present Data on Anterior and Posterior Segment Drug Product Candidates at the Association for Research in Vision and Ophthalmology (ARVO) Annual Meeting
May 02, 2017
Ocular Therapeutix™ to Report First Quarter 2017 Financial Results
May 01, 2017
Ocular Therapeutix™ to Present Additional Phase 3 Data and Patient Reported Outcomes Results for DEXTENZA™ at the American Society of Cataract and Refractive Surgery (ASCRS) Symposium
April 24, 2017
Ocular Therapeutix™ Appoints George Migausky as Interim Chief Financial Officer
April 06, 2017
New Publication Describes Positive Patient Experience in Study of Ocular Therapeutix’ DEXTENZA™ Following Cataract Surgery
March 15, 2017
Ocular Therapeutix™ Reports Fourth Quarter and Full Year 2016 Financial Results
March 10, 2017
Ocular Therapeutix™ to Report Fourth Quarter and Full Year 2016 Financial Results
March 08, 2017
Ocular Therapeutix™ Announces FDA Acceptance of NDA Resubmission for DEXTENZA™ for the Treatment of Ocular Pain Occurring After Ophthalmic Surgery
February 22, 2017
Ocular Therapeutix™ to Present at Three Upcoming Investor Conferences
February 09, 2017
Ocular Therapeutix, Inc. Announces Pricing of Public Offering of Common Stock
January 24, 2017
Ocular Therapeutix™ Resubmits NDA for DEXTENZA™ for the Treatment of Ocular Pain Occurring After Ophthalmic Surgery
January 23, 2017
Ocular Therapeutix, Inc. Announces Public Offering of Common Stock
January 23, 2017
Ocular Therapeutix™ Announces Additional Successful Results for Phase 3 Clinical Trial of DEXTENZA™
January 04, 2017
